Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 33Lymphoma, Follicular 13Lymphoma, Large B-Cell, Diffuse 11Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 5Recurrence 4Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, Mantle-Cell 3Neoplasms 2Leukemia, Plasma Cell 2Smoldering Multiple Myeloma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1HTLV-I Infections 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 9fludarabine 7Dexamethasone 7pomalidomide 6Rituximab 6pembrolizumab 5selinexor 4obinutuzumab 4glofitamab 4Lenalidomide 4daratumumab 3belantamab mafodotin 3Temozolomide 3Gemcitabine 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2fludarabine phosphate 2enzalutamide 2cemiplimab 2carfilzomib 2abemaciclib 2PF06821497 2Mesna 2Lisaftoclax 2Injections 2Immunotherapy, Adoptive 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrence × Lenalidomide × 30 days × Clear all
NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-05-06

OLYMPIA-5

Regeneron Pharmaceuticals

Phase 3 Recruiting
470 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04712097 2026-05-05

Celestimo

Hoffmann-La Roche

Phase 3 Active not recruiting
478 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡